Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ACHV vs PRPO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACHV Captures Overall Composite Edge (56.6 HOLD vs 32.2 SELL), While PRPO Leads 4–2 on Growth & Valuation Pillars

ACHV Overall Winner 6-Pillar Tally: ACHV 2 – 4 PRPO Matrix Metrics: ACHV 6 – 4 PRPO

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Precipio, Inc. (PRPO) on higher Unified Composite conviction (56.6/100 HOLD vs. 32.2/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while PRPO wins 4–2 across the 6-pillar growth and valuation breakdown. ACHV trades at $6.78 (35.3x Forward P/E, 0.0% operating margin) versus PRPO at $20.35 (15.4x Forward P/E, -5.3% operating margin).

  • Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. PRPO 32.2/100 SELL) and 1.73β · 62% Vol risk profile, whereas PRPO leads top-line expansion (+8.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACHV vs PRPO
ACHV NASDAQ Head-to-Head Winner
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28
PRPO NASDAQ
Precipio, Inc. Common Stock
Laboratory Analytical Instruments
$20.35
-8.04% 1D
Market Cap $40.2M
TTM Revenue $28M
Forward P/E 15.4x
Beta / 30D Vol 1.21β · 96% Vol
Unified Composite Score
32.2 / 100 SELL
Tech 5.0 Fund 31.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.1 · SMA20: $20.38 · SMA50: $22.83

6-Pillar Scorecard Institutional Category Breakdown (ACHV 2 – 4 PRPO)

Columns: Metric · ACHV · PRPO
1. Valuation Multiples PRPO
Forward P/E 35.3x 15.4x
Trailing P/E 35.3x 15.4x
PEG Ratio 17.68x N/M
EV / Revenue N/M 1.4x
2. Growth & Scale PRPO
Revenue Growth (YoY) +0.0% +8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $28M
Market Cap $692.8M $40.2M
3. Profitability & Quality ACHV
Gross Margin N/A 44.6%
Operating Margin 0.0% -5.3%
Net Profit Margin 0.0% -4.1%
Return on Equity (ROE) -845.0% -8.0%
4. Balance Sheet & Cash Flow PRPO
Cash Generation (TTM) -$44M -$56,000 EBITDA
Cash Flow Margin N/A -0.2% EBITDA Mgn
Net Cash / Leverage $46M Net Cash $8.29 Book/Sh · -8.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACHV
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 88.3% (23rd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat PRPO
OpEx & R&D Intensity N/A 49.9% of Rev ($14M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACHV (6) vs PRPO (4)
Institutional Metric ACHV PRPO Criterion Row Edge
Market Capitalization
Scale
$692.8M $40.2M Larger Scale ACHV
Trailing P/E Ratio
Valuation
35.3x 15.4x Lower Multiple PRPO
Forward P/E Ratio
Valuation
35.3x 15.4x Lower Multiple PRPO
Revenue Growth (YoY)
Growth
+0.0% +8.3% Higher Growth PRPO
Operating Margin (TTM)
Profitability
0.0% -5.3% Higher Margin ACHV
Net Profit Margin
Profitability
0.0% -4.1% Higher Margin ACHV
Return on Equity (ROE)
Capital Efficiency
-845.0% -8.0% Higher ROE PRPO
52-Week Range Position
Momentum
69% ($3–$9) 16% ($18–$34) Stronger Trend ACHV
Beta / 30D Volatility
Risk Regime
1.73β · 62% Vol 1.21β · 96% Vol Lower Realized Risk ACHV
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 32.2 / 100 (SELL) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
N/A $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.68x PEG · N/M EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$44M ($46M Net Cash) -$56,000 EBITDA ($8.29 Book/Sh · -8.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRPO +4.52 pp
ACHV: -8.5% · PRPO: -3.98%
3M Horizon ACHV +0.82 pp
ACHV: +0.15% · PRPO: -0.67%
6M Horizon ACHV +43.3 pp
ACHV: +21.29% · PRPO: -22.01%
1Y Horizon ACHV +32.64 pp
ACHV: +43.64% · PRPO: +11.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs PRPO. Trailing 12-month operating profitability (ACHV 0.0% vs PRPO -5.3%) and valuation multiples (ACHV 35.3x vs PRPO 15.4x Forward P/E) are benchmarked directly in Pillar 4 below.

ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x
PRPO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin44.6%
Op. Margin-5.3%
ROE / Fwd P/E-8.0% · 15.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRPO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PRPO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRPO Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $40.2M market capitalization and -5.3% operating margin.
OpEx & R&D Reinvestment 49.9% of Rev ($14M)
90D Engineering Disclosures 0 Published

Investor FAQ ACHV vs PRPO Key Questions & Quantitative Answers

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Precipio, Inc. (PRPO) on higher Unified Composite conviction (56.6/100 HOLD vs. 32.2/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Options & Positioning), while PRPO wins 4–2 across the 6-pillar growth and valuation breakdown. ACHV trades at $6.78 (35.3x Forward P/E, 0.0% operating margin) versus PRPO at $20.35 (15.4x Forward P/E, -5.3% operating margin). Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. PRPO 32.2/100 SELL) and 1.73β · 62% Vol risk profile, whereas PRPO leads top-line expansion (+8.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

PRPO leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PRPO at +8.3% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (44.6% gross margin, -5.3% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus $28M for PRPO. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus 49.9% of Rev ($14M) (0 disclosures) for PRPO.

PRPO screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas PRPO trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-0.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus PRPO (-8.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, PRPO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.21β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.